mRNA-4659
Phase 1RNA therapy
ModernamRNA-4659 is one of 41 therapeutic programs targeting Ovarian Carcinoma. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
69 competitors in Ovarian Carcinoma
#DrugCompanyPhaseTrials
1Tecentriq
RochePhase 3
Jemperli
GGlaxo Dba Glaxosmithkline
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Taxol
TevaPhase 2
Nolvadex
AstraZenecaPhase 2
Veliparib
AbbViePhase 3
Eloxatin
TevaPhase 2
Stivarga
BayerPhase 2
Lynparza
AstraZenecaPhase 2
Caelyx
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for mRNA-4659. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy
- Highest Phase
- Phase 1
- Company